US Patent Issued to Fulu Labs on Feb. 10 for "Nuclease-dendrimer formulations for Covid-19 and broad-spectrum antiviral therapy and prophylaxis" (Texas, California Inventors)

ALEXANDRIA, Va., Feb. 11 -- United States Patent no. 12,544,447, issued on Feb. 10, was assigned to Fulu Labs Corp. (Houston).

"Nuclease-dendrimer formulations for Covid-19 and broad-spectrum antiviral therapy and prophylaxis" was invented by Xiaohua Su (Houston) and Leonid I. Rudin (San Marino, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Compositions of nucleases in formulations with dendrimers are used in pharmaceutically effective dosages as therapeutics for covid-19 and a broad spectrum of viruses in various embodiments. When cationized nucleases are mixed and/or complexed with a dendrimer, an unexpected positive dendrimer effect is manifest. This positive dendrimer effect is shown to be highly...